iBio, Inc. (IBIO)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Jun 30
In fiscal 2026, iBio, Inc. reported revenue of $100.0K, down 75.0% from the prior year. The company ran a net loss, with a net margin of -33044.0%. It held $99.11M in total assets against $13.40M in total liabilities.
Key ratios (FY2026)
-35141.0%
Operating margin
-33044.0%
Net margin
-38.6%
Return on equity
-75.0%
Revenue growth (YoY)
| Metric (FY) | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $100.0K | $400.0K | $225.0K | $0 | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | $216.0K | $1.46M | $703.0K | — | — | — |
| Gross Profit | — | — | — | — | $2.17M | $909.0K | $935.0K | — | — | — |
| Operating Income | -$35.14M | -$18.60M | -$16.63M | -$29.34M | -$29.70M | -$31.11M | -$14.00M | -$15.79M | -$14.23M | -$14.27M |
| Net Income | -$33.04M | -$18.38M | -$24.91M | -$65.01M | -$50.30M | -$23.21M | -$16.44M | -$17.59M | -$16.11M | -$14.53M |
| EPS (Diluted) | $-0.32 | $-1.75 | $-6.50 | $-106.19 | $-5.78 | $-3.00 | — | — | — | — |
| Total Assets | $99.11M | $23.18M | $28.73M | $41.21M | $99.41M | $146.97M | $94.19M | $30.59M | $43.08M | $36.01M |
| Total Liabilities | $13.40M | $8.30M | $7.41M | $25.83M | $35.92M | $38.40M | $37.58M | $28.13M | $26.92M | $27.09M |
| Shareholders' Equity | $85.71M | $14.88M | $21.32M | $15.38M | $63.48M | $108.58M | $56.62M | $2.46M | $16.17M | $8.91M |
| Cash & Equivalents | $56.40M | $8.58M | $14.21M | $4.30M | $22.68M | $77.40M | $55.11M | $4.42M | $4.42M | $15.93M |
| Operating Cash Flow | -$23.22M | -$15.30M | -$18.55M | -$30.44M | -$37.48M | -$30.06M | -$13.35M | -$13.97M | -$13.48M | -$13.16M |
| Capital Expenditures | $578.0K | $16.0K | $210.0K | $5.74M | $7.33M | $4.92M | $1.08M | $920.0K | $934.0K | $1.32M |
| Shares Outstanding | 55.70M | 19.35M | 8.62M | 1.02M | 8.73M | 8.71M | 140.07M | 20.15M | 16.04M | 8.91M |